https://scholars.lib.ntu.edu.tw/handle/123456789/495053
標題: | Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells | 作者: | Lee Y.-C Lee L.-M CHIH-HSIN YANG Lin A.M.-Y Huang Y.-C Hsu C.-C Chen M.-S Chi C.-W Yin P.-H Kuo C.-D Liao J.-F Lee H.-C. |
關鍵字: | Epidermal growth factor receptor; Lung cancer; Norcantharidin | 公開日期: | 2013 | 卷: | 29 | 期: | 1 | 起(迄)頁: | 237-243 | 來源出版物: | Oncology Reports | 摘要: | Norcantharidin is the demethylated analog of cantharidin isolated from blister beetles (Mylabris phalerata Pall.). In this study, we evaluated whether norcantharidin exhibits anticancer effects against the human non-small cell lung cancer cell lines A549 (epidermal growth factor receptor (EGFR) mutation-negative) and PC9 (EGFR mutation-positive). Our results revealed that norcantharidin dose-dependently retards cell growth, arrests cell cycle at G2/M phase, reduces cell migration, and even induces apoptosis at the concentration of 100 μM. Moreover, we found that norcantharidin enhances the anticancer effects of gefitinib and cisplatin. Norcantharidin exhibited similar potency of anticancer effects against the two cell lines with different EGFR mutation status and did not affect EGF-induced EGFR phosphorylation, suggesting that the EGFR signaling may not be the target of norcantharidin. In conclusion, our results suggest that norcantharidin exhibits anticancer effects against non-small cell lung cancer cells in vitro and support its potential as a chemotherapeutic agent for treating non-small cell lung cancer. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872850504&doi=10.3892%2for.2012.2118&partnerID=40&md5=cf7fd86cfe7004ba582c331ab7e3967f https://scholars.lib.ntu.edu.tw/handle/123456789/495053 |
ISSN: | 1021-335X | DOI: | 10.3892/or.2012.2118 | SDG/關鍵字: | cisplatin; epidermal growth factor receptor; gefitinib; norcantharidin; antineoplastic activity; apoptosis; article; cancer cell; cancer inhibition; cell migration; concentration response; controlled study; drug potency; drug potentiation; drug targeting; EGFR gene; G2 phase cell cycle checkpoint; gene mutation; human; human cell; lung non small cell cancer; priority journal; protein phosphorylation; signal transduction; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bicyclo Compounds, Heterocyclic; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; Flow Cytometry; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Receptor, Epidermal Growth Factor; Signal Transduction; Tumor Cells, Cultured |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。